SAM
ORIC icon

Shell Asset Management’s Oric Pharmaceuticals ORIC Stock Holding History

Shell Asset Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,836
Closed -$49K – 1242
2025
Q2 		$49K Sell
4,836
-3,636
-43% -$24.4K ﹤0.01% 1151
2025
Q1 		$47K Sell
8,472
-352
-4% -$3.08K ﹤0.01% 1160
2024
Q4 		$71K Hold
8,824
– – ﹤0.01% 1118
2024
Q3 		$90K Buy
+8,824
New +$87.2K ﹤0.01% 1068
2024
Q1 		$63K Buy
+8,965
New +$106K ﹤0.01% 1124

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Shell Asset Management's ORIC Position: Q3 2025 in Review

Shell Asset Management sold out of Oric Pharmaceuticals (ORIC) in Q3 2025, closing a stake of 4,836 shares — an estimated $49K sold.

Shell Asset Management first reported a position in ORIC in Q1 2024 and held it in 5 quarters. The position peaked at $90K in Q3 2024. 152 funds tracked by Wall St. Rank hold ORIC as of Q3 2025.

  • Shell Asset Management reported no remaining Oric Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Shell Asset Management sold 4,836 Oric Pharmaceuticals shares in Q3 2025, an estimated $49K.
  • Shell Asset Management first reported a position in Oric Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Shell Asset Management's Oric Pharmaceuticals position peaked at $90K in Q3 2024.
  • 152 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.